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In relation to commonly used no-observed-adverse-effect-level (NOAEL) point 
of depature, because of its statistical power and reliability, Benchmark dose (BMD) 
approach has been proposed as an alternative in dose-response assessment. The aim of 
this study was to derive BMD (10%) by means of PROAST software to quantify 
influence of cadmium (Cd) and/or decabrominated diphenyl ether (BDE209) on thyroid 
hormones homestasis. Study was conducted on male Wistar rats treated orally by 
gavage for 28 days by either single substances or their combination. Three groups of 
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animals were dosed with Cd at levels of 2.5, 7.5 and 15 mg/kg b.w./day, three groups of  
animals were dosed with BDE209 at levels of 1000, 2000 or 4000 mg/kg b.w./day, 
while 9 groups received different dose mixtures of previously given dose levels of Cd 
and BDE209 (design 3 x 3). Results of the study have indicated that Cd+BDE209 
mixtures are likely more potent to disrupt thyroid function than would be expected from 
the chemicals individually. Derived BMD – lower confidence limits (BMDL), if ratio 
BMD/BMDL is < 10,  were 9.4 mg Cd/kg b.w./day and 2155 mg BDE209/kg b.w./day 
for the effect on T3; and 6.22 mg Cd/kg b.w./day in the mixture with BDE209 2000 
mg/kg b.w./day for the effect on FT3.  
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Humans and all other organisms are typically exposed to multi-
component chemical mixtures, present in the surrounding environmental media 
(water, air, soil), in food or in consumer products. However, chemical risk 
assessment usually considers the effects of single substances in isolation, an 
approach that is only justified if the exposure to mixtures does not bear the risk 
of an increased toxicity. Furthermore, there is strong evidence that chemicals 
with common specific modes of action work together to produce combination 
effects that are larger than the effects of each mixture component applied singly 
(1-3). Fewer studies have been conducted with mixtures composed of chemicals 
with diverse modes of action (4, 5), with results clearly pointing in the same 
direction: the effects of such mixtures are also higher than those of the 
individual components. Of particular interest, as reported within the findings of 
a project on mixture toxicology and ecotoxicology commissioned by the 
European Commission, DG Environment (4, 5) is to examine joint action 
chemicals of which cadmium (Cd) as relatively known environmental 
contaminant and novel one decabrominated diphenyl ether (BDE209) are the 
subject of the present work. It has been demonstrated that acute or chronic Cd 
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exposure could result in toxic effects especially associated with targets such as 
liver, kidney, bone, lungs and testes in humans and experimental animals (6, 7). 
The available literature provides some data concerning Cd effects on thyroid 
gland (8-11) as well as estrogen like effects, referred in recent publication of 
Imran et al. (2010) (12). Recent studies with BDE209 have shown that it 
disturbs hepatic enzyme activity and thyroid hormone function (13-17), causes a 
decrease in epididymal sperm functions (18), and has potential neurotoxic and 
neonatal risks (19, 20). However, there are no available data on Cd and 
BDE209 combined toxicity, which is of utmost interest and particularly in the 
light of thyroid disfunction as a subtle and critical event for neurodevelopmental 
toxicity of various chemicals (21).  
Our recently published results based on mechanistic interpretation have 
indicated that Cd-BDE209 mixtures are likely more potent to disrupt thyroid 
function than would be expected from the chemicals individually (22). In order 
to exam dose-response relationship unlike tradionaly used no-observed-adverse-
effect-level (NOAEL) approch, in this study we calculated benchmark dose for 
the effect of 10% towards controls (BMD10) recommended by European Food 
Safety Authority (EFSA) in 2009 (23) for analysing dose-response data from 
experimental studies. Namely, the EFSA Scientific Committee concluded that 
the BMD approach is a scientifically more advanced method to the NOAEL 
approach for deriving a Reference Point (RP). Further on, during last year 
EFSA released into public technical report on use of PROAST software 
packages for applying the BMD approach in risk assessment (24), which we 
applied to model the effect of BDE209 and Cd on T3, T4, FT3 and FT4 level in 
rat subacutely exposed to single chemical or their mixture. 
2. Materials and methods 
2.1. Experimental animals 
Male albino Wistar rats weighing 200-240 g were obtained from the 
disease free stock of the animal house of Military Medical Academy, Belgrade. 
The animals were housed in plastic cages with plastic bottom and wire mesh 
top, in climate-controlled facility with a constant day–night cycle (12 h/12h 
light-dark ratio) at a temperature of 20-24 °C and relative humidity between 40 
and 60%. Food and tap water were offered ad libitum throughout the study. The 
experimental animals were treated according to the Guidelines for Animal 
Study No. 9667-1/2011 (Ethics Committee of the Military Medical Academy, 
Belgrade, Serbia).  
After a quarantine period of 14 days, groups of 8 animals were treated 
orally by gavage for 28 days either by single substances or their combination in 
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a volume of 0.5 mL/kg bw. Three groups of  animals were dosed with 2.5, 7.5 
and 15 mg Cd/kg b.w./day, calculated to Cd (groups were assigned as Cd 2.5, 
Cd 7.5 and Cd 15, respectively), three groups of  animals were dosed with 1000, 
2000 or 4000 mg BDE209/kg b.w./day (groups were assigned as BDE209 1000, 
BDE209 2000 and BDE209 4000, respectively), while 9 groups received 
different dose mixtures of previously given dose levels of Cd and BDE209 
(design 3 x 3). Cd salt and BDE209 were dissolved in dimethyl sulfoxide 
(DMSO) prior to application. Rats in the vehicle control group received by 
gavage the vehicle only (DMSO group), while animals in control group 
received certain amount of saline solution (control group). Doses of Cd used in 
experiment have been chosen to reflect environmental to occupational exposure 
(6, 25) doses of BDE209 have been chosen based on experiments where similar 
endpoints were examined (26). 
Blood was collected after decapitation from the carotid arteries in glass 
tubes, and then centrifuged at 3000×g for 30 min. The supernatant (serum) was 
transferred to polypropylene test tubes and stored at −70 ◦C until thyroid 
hormones analysed.  
2.2. Chemicals 
Cadmium-chloride (CdCl2 x H2O) was purchased from Merck 
(Darmastadt, Germany) while BDE209 (98% pure) and dimethyl sulfoxide 
(DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA).   
2.3. Hormone analysis 
Serum samples were analyzed for thyroid-stimulating hormone (TSH), 
thyroxin (T4), free thyroxin (FT4),  triiodothyronin (T3) and free 
triiodothyronin (FT3) using commercial tests on Roche Elecsys 2010 (Roche 
Diagnostics, Mannheim, Germany). Values for T3 and T4 are expressed as 
nmol/L, for FT3 and FT4 as pmol/L while for TSH as mIU/L. 
2.4. Statistical analysis 
For the modelling of dose response relationship the data were analysed by 
the BMD approach, using the PROAST software (24, 27). In this approach, the 
dose–response data are statistically evaluated in general, by fitting a dose–
response model to the data. In the present study associated BMD10 (10 % was 
used as the practical default) (23). For most parameters, a BMD at this level 
appears to approximate the limit between adversity and adaptivity, based on the 
pathophysiology of the effect under experimental conditions in the rat. In 
addition, this default level also seems to be close to the within-animal variation 
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(28, 29). The choice of the model for deriving the BMD follows from a 
procedure of selecting a model from the following nested family of models: 
model 1: y = a; model 2: y = a exp(b x); model 3: y = a exp(b xd); model 
4: y = a (c−(c−1)) exp(b x) or model 5: y = a (c−(c−1)) exp(b xd), assigned in 
figures as E1, E2, E3, E4 or E5, respectively. In these models the parameter a 
represents the background response; the parameter b reflects the ‘slope’ or the 
‘strength’ of the response, c is maximal response relative to the background 
level, and d steepness (27). To account for statistical errors in the dose–response 
data, the confidence interval around the BMD (statistical lower confidence limit 
of BMD - BMDL) is calculated as well. The BMD/BMDL ratio was used as a 
measure for the (statistical) uncertainty in a data set. In case of a more than ten-
fold difference between BMD and BMDL, the data were considered 
uninformative. For graphical presentation on a log-dose scale, an arbitrary value 
(but lower than the lowest dose) is used for plotting dose zero. 
3. Results 
In the present work dose-response relationship has been established and 
accordingly BMD10 and BMDL were derived for single chemical treatments as 
well as their mixture (Table I).  
Exponential models were used for all data sets, while among them, model 
E4 was used in majority of cases. Exceptions were as follow: model E1 for the 
effect of BDE209 on FT3, and model E2 for the effects of Cd on T3, 
Cd+BDE209 2000 on FT3 and BDE209 on T3 and T4. Results obtained for 
TSH could not be used for further data analysis since all the values were below 
the limit of detection. Dose response model for the effect on T4 and FT4 did not 
change after adding different doses of BDE 209 to Cd, and for all tested sets of 
data model was the same, E4: y = a (c−(c−1)) exp(b x). In the case of hormone 
T3 starting model E2 for Cd or E1 for BDE209, changed to the E4 for their 
mixture without further changes in a dose dependent manner. Unlike dose-
response model for T3, effect of Cd on FT3, T4 and FT4 could be described by 
model E4. Concerning FT3 hormone, addition of BDE209 changed the model 
proposed for BDE209. However, in comparison with the model initially fitted 
for Cd, addition of the first dose of BDE209 in the mixture did not change the 
model, whereas the next two higher doses lead to model change. Concerning T4 
and FT4, mixtures have been defined by E4 model. It should be mentioned that 
in case of T4 hormone proposed model for a single compound BDE209 has 
changed from E2 to E4 when combined with Cd.  Illustration of model fitted for 




Table I Benchmark dose levels for the influence of Cd and/or BDE209 on  
 thyroid hormones homeostasis  
 
Treatment  T3 FT3 T4 FT4 
Cd 
BMD 15.2 0.0454 0.5771 0.4929 
BMDL 9.4 0.0014 0.0030 0.0025 
BMD/BMDL  1.6 32.4 192.3 197.2 
Cd  + BDE209 
1000 
BMD 1.0 0.0462 0.0339 0.0323 
BMDL 0.0020 0.0012 0.0013 0.0013 
BMD/BMDL  500 38.3 26.1 24.8 
Cd  + BDE209 
2000 
BMD 0.9501 11 0.0290 0.0281 
BMDL 0.0018 6.2201 0.0017 0.0013 
BMD/BMDL  527.8 1.8 17.1 21.6 
Cd  + BDE209 
4000 
BMD 0.0972 0.0454 0.0339 0.0281 
BMDL 0.001 0.0013 0.0013 0.0013 
BMD/BMDL  97.2 34.9 26.1 21.6 
BDE209 
BMD 3266 / 16.7 18.9 
BMDL 2155 / 0.0270 0.0330 
BMD/BMDL  1.5 / 618.1 572.7 
 
Cd - groups dosed with 2.5, 7.5 or 15 mg Cd/kg b.w./day;  
Cd + BDE209 1000 - groups dosed with 2.5, 7.5 or 15 mg Cd/kg b.w./day and    
                                 1000 mg BDE209/ kg b.w./day;  
Cd + BDE209 2000 - groups dosed with 2.5, 7.5 or 15 mg Cd/kg b.w./day and  
   2000 mg BDE209/ kg b.w./day;  
Cd + BDE209 4000 - groups dosed with 2.5, 7.5 or 15 mg Cd/kg b.w./day and  
   4000 mg BDE209/ kg b.w./day;  
BDE209 - groups dosed with 1000, 2000 or 4000 mg BDE209/kg b.w./day;       
the BMD/BMDL ratio < 10 was considered to be of relevance (grey highlighted   
cells). 
 
In general, BMDL decreased from Cd groups over Cd plus BDE209 
groups (Table I). In the case of T3, decrease of BMDL is followed by an 
increase of BDE209 dose in the mixture and the lowest calculated BMDL for 
T3 (0.0010 mg Cd/kg b.w./day) was obtained for the mixture of Cd and the 
highest dose of BDE209. For FT3 the lowest BMDL was 0.0012 mg Cd/kg 
b.w./day, but for the mixture of Cd and the lowest dose of BDE209. The lowest 
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derived BMDL was 0.0013 mg Cd/kg b.w./day in the mixture with BDE209 
1000 or 4000, for the effect on T4 hormone. For the all mixtures of chemicals, 
derived BMDL for the effect on FT4 was 0.0013 mg Cd/kg b.w./day.  
Illustration of model fitted for the effects of mixtures of Cd and BDE209 
on FT3 is presented on the Figure 1.  
 
Figure 1.  Dose–response curves for the effects on T3 and FT3, analysed  
 against external dose of Cd, BDE209 or mixture of Cd with  
 BDE209.  
 
Parameter a is the background (control) level, b reflects the efficacy of exposure 
(slope), c maximal response relative to the background level, d steepness. Log 
likelihood is used to assess to what extent the described curve deviates from no effect (y 
= a). Critical effect size (CES on the figures), for these endpoints set at 10% (horizontal 
dotted lines); a corresponding critical effect dose (CED on the figures=Benchmark 
dose-BMD) is represented by the vertical dotted line; L05 and L95 represent the lower 
and upper bounds of the 90% confidence interval. Exposure dose (X-axis) is on a 
logarithmic scale. 
4. Discussion 
Our recently published results have demonstrated that subacute exposure 
to a mixture of BDE209 and Cd has adverse effects on thyroid hormone 
homeostasis in adult male rats to a larger extent than BDE209 or Cd alone (22). 
Application of different doses of BDE209 resulted in statistically significant 
decrease but in the following hormone levels:  FT3, T4 decreased after 
application of BDE209 in dose of 1000 mg BDE209/kg b.w./day, while FT3, 
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T4, FT4 after administration of 2000 mg BDE209/kg b.w./day, and T3 after 
axposure to 4000 mg BDE209/kg b.w./day. Similary, significant decrease in 
FT4 was obtained after 2.5 mg Cd/kg b.w./day, in FT3, T4 levels after 7.5 mg 
Cd/kg b.w./day and in FT3 after 15 mg Cd/kg b.w./day. Contribution of mixture 
was seen when doses of 1000 or 2000 mg BDE209/kg b.w./day were given 
along with all three doses of Cd inducing decrease in T3, T4 or FT4 levels in 
comparison with corresponding dose levels of either Cd or BDE209 (22).   
Results of different studies have also shown that Cd and BDE209 per se 
may influence thyroid function (30-39). Thyroid dysfunction might be related to 
structural damage of thyroid follicular cells due to accumulation of Cd in the 
thyroid gland (40-42), whereas PBDEs have been shown to bind to thyroid 
receptors (TRs) and perhaps have selective effects on TRs function thus 
belonging to the group of environmental chemicals that act as thyroid hormone 
analogues (31, 32, 43-45).  
Phenomenon related to combined Cd and BDE209 toxicity was planned 
to be defined in a dose-related manner by the use of PROAST software (24, 27). 
Traditionally, when experimental animal data are used for risk assessment of 
substances, which are not genotoxic and carcinogenic, the NOAEL and/or the 
Lowest-Observed-Adverse-Effect-Level (LOAEL) for the critical effect of a 
substance, forms the RP for deriving health-based guidance values, such as an 
Acceptable Daily Intake (ADI). However, while this approach may utilise 
qualitative information, it does not use the data available in a quantitative way. 
In contrast, the BMD approach makes extended use of the dose-response data 
from studies in experimental animals or from observational epidemiological 
studies to better characterise and quantify potential risks. After comparing the 
strengths and weaknesses of the BMD and NOAEL approaches for deriving RP 
for risk assessment, it has been concluded that the BMD approach is a 
scientifically more advanced method to the NOAEL approach for deriving a 
RP, since it makes extended use of available dose-response data and it provides 
a quantification of the uncertainties in the dose-response data (23). Using the 
BMD approach also results in a more consistent RP, as a consequence of the 
specified benchmark response. 
In the present study for all treated groups exponential models were fitted, 
and accordingly BMD and BMDL values were calculated. However, only in the 
cases where  BMD/BMDL ratio was lower than 10, i.e. 9.4 mg Cd/kg b.w./day 
and  2155 mg BDE209/kg b.w./day for the effect on T3; and 6.22 mg Cd/kg 
b.w./day in mixture with BDE209 2000 mg/kg b.w./day for the effect on FT3, 
which means that this BMDL could be used as point of departure for further 
steps in risk analysis (23) (Table I). 
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5. Conclusion 
Application of PROAST software for the effects of Cd and/or BDE209 
on thyroid hormone levels confirmed dose-response relationship for both single 
chemicals and mixture treatment. Some of the resultant BMDL doses may be 
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Kratak sadržaj 
Primena statistički dobijene Benchmark doze (BMD) u proceni rizika predstavlja 
alternativu najčešće korišćenoj „dozi bez štetnog efekta” (NOAEL)  zbog veće 
pouzdanosti u analizi odnosa doze i toksičnog efekta. Cilj ovog rada bio je 
izračunavanje BMD (10%) primenom PROAST softvera radi kvantitativne procene 
uticaja Cd i/ili BDE209 na homeostazu hormona štitaste žlezde. Ispitivanje je 
sprovedeno na mužjacima Wistar pacova koji su putem oralne sonde, tokom 28 dana, 
primali pojedinačne supstance ili njihove kombinacije. Kadmijum je primenjivan u 
dozama od 2,5, 7,5 i 15 mg Cd/kg t.m./dan, a BDE209 u dozama od 1000, 2000 i 4000 
mg BDE209/kg t.m./dan, dok je ostalih devet grupa životinja primalo kombinacije 
hemikalija (dizajn 3 x 3). Rezultati studije ukazuju da smeša Cd i BDE209 verovatno 
izaziva intenzivniji poremećaj funkcije štitaste žlezde nego svaka od supstanci 
pojedinačno. Izračunate Benchmark doze (10%), odnosno odgovarajuće donje granice 
pouzdanosti (BMDL), uz uslov da je BMD/BMDL < 10, iznose 9,4 mg Cd/kg t.m./dan i 
2155 mg BDE209/kg t.m./dan za efekte na T3 hormon, a za efekat na FT3 hormon 6,22 
mg Cd/kg t.m/dan u smeši sa BDE209 od 2000 mg/kg. 
Ključne reči: doza-odgovor; dekabromovani difeniletar; kadmijum;  
     hormoni štitaste žlezde; smeša. 
